https://www.home.saxo/fr-be/markets/stocks/bmea-xnas
Biomea Fusion Inc action | Saxo Bank
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat...
biomeafusionincactionsaxo
https://www.home.saxo/fr-fr/markets/stocks/bmea-xnas
Biomea Fusion Inc action | Saxo Banque
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat...
biomeafusionincactionsaxo
https://www.finanznachrichten.de/nachrichten-2026-03/68088273-biomea-fusion-inc-biomea-fusion-announces-first-patient-dosed-in-newly-initiated-phase-ii-programs-enrolling-type-2-diabetes-patients-failing-on-st-399.htm
Biomea Fusion, Inc.: Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II...
COVALENT-211 Phase II enrolling insulin-deficient type 2 diabetes patients COVALENT-212 Phase II enrolling type 2 diabetes patients uncontrolled with a GLP-1...
https://www.biospace.com/press-releases/biomea-fusion-to-become-a-diabetes-obesity-medicines-company
Biomea Fusion to Become a Diabetes & Obesity Medicines Company - BioSpace
to become abiomeafusiondiabetesobesity
https://www.biospace.com/press-releases/biomea-fusion-presents-new-preclinical-and-clinical-data-on-icovamenib-at-the-85th-scientific-sessions-of-the-american-diabetes-association-ada
Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific...
https://www.biospace.com/biomea-fusion-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference
Biomea Fusion to Present at the 40th Annual J.P. Morgan Healthcare Conference - BioSpace
Dec 21, 2021 - Biomea Fusion, Inc. announced that it will present at the upcoming virtual 40th Annual J.P. Morgan Healthcare Conference.
https://www.home.saxo/en-sg/markets/stocks/bmea-xnas
Biomea Fusion Inc stock | Saxo
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat...
biomeafusionincstocksaxo
https://www.fiercebiotech.com/ai-and-machine-learning/biomea-cuts-35-staff-drops-leukemia-asset-shift-metabolic-focus
Biomea cuts staff, drops leukemia asset in metabolic shift
May 5, 2025 - Biomea is homing in on lead asset icovamenib, a menin inhibitor designed to address the underlying cause of diabetes, and a preclinical GLP-1 agonist.
biomeacutsstaffdropsleukemia
https://www.fxempire.com/stocks/bmea/financials
Biomea Fusion, Inc. Common Stock (BMEA) Income Statement | FXEmpire
Explore comprehensive financial statements of Biomea Fusion, Inc. Common Stock (BMEA). In-depth analysis of BMEA's earnings, revenue trends, and...
common stockincome statementbiomeafusionbmea
https://www.macrotrends.net/stocks/charts/BMEA/biomea-fusion/ebitda
Biomea Fusion EBITDA 2020-2026 | BMEA | MacroTrends
Biomea Fusion ebitda from 2020 to 2026. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
biomeafusionebitda20202026
https://www.biospace.com/biomea-fusion-reports-second-quarter-2024-financial-results-and-corporate-highlights
Biomea Fusion Reports Second Quarter 2024 Financial Results and Corporate Highlights - BioSpace
2024 financial resultssecond quarter
https://www.fxempire.com/stocks/bmea/profile
BMEA: Biomea Fusion, Inc. Common Stock Company Profile & Statistics | FXEmpire
Dive into the Biomea Fusion, Inc. Common Stock (BMEA) company profile. Key financial ratios, comprehensive company statistics, and essential BMEA data, all in...
common stock companybmeabiomeafusioninc
https://investingnews.com/biomea-fusion-announces-poster-presentations-of-icovamenib-at-the-american-diabetes-association-86th-scientific-sessions/
Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association...
May 5, 2026 - Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion" or "the Company") (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that three...
poster presentations
https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bmea/biomea-fusion/news/can-biomea-fusion-nasdaqbmea-afford-to-invest-in-growth
Can Biomea Fusion (NASDAQ:BMEA) Afford To Invest In Growth? - Simply Wall St News
We can readily understand why investors are attracted to unprofitable companies. For example, although...
https://www.benzinga.com/24/12/42533677/why-is-diabetes-drug-developer-biomea-fusion-stock-trading-lower-on-tuesday
Why Is Diabetes-Drug Developer Biomea Fusion Stock Trading Lower On Tuesday? - Biomea Fusion...
Dec 17, 2024 - Biomea Fusion's COVALENT-111 study shows icovamenib reduces HbA1c significantly in T2D patients, with no safety concerns or drug interactions.